Clover Corporation Limited · ASX:CLV
Clover — Shareholder Meeting (November 2026)
38 slides from Clover's shareholder meeting presentation, Nov 17, 2026
Slide 1: FY26 Annual General Meeting
rsonal use only FY26 Annual General Meeting 17 November 2026 Chair Rupert Harrington CEO Peter Davey
Slide 2: Welcome
Clover rsonal use only Corporation Limited Welcome FY26 Annual General Meeting 2
Slide 3: Board members
Board members rsonal use only Rupert Harrington Peter Davey Toni Brendish Chair Managing Director & CEO Non-Executive Director Brett Hewlett Dr. Simon Green Ian Glasson Fiona Pearse Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director 3
Slide 4: Agenda
Agenda Formal business rsonal use only 02 Welcome 24 Item 1 – Adoption of annual accounts 03 Introductions 25 Item 2 – Resolution 1: Adoption of remuneration report 05 How to ask questions 26 Item 3 – Resolution 2: Re-election of Mr. Ian Glasson 06 How to vote 28 Item 4 – Resolution 3: Re-election o
Slide 5: How to ask a question
How to ask a questions • To ask a written question select rsonal use only the Q&A icon • Select the topic your question relates to from the drop-down list • Type your question in the text box and press the send button • To ask a verbal question follow the instructions below the broadcast window. 5
Slide 6: How to vote
How to vote • When the poll is open, select the rsonal use only vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote, “click here to change your vote” at any time until the poll is closed 6
Slide 7: Chairman's Address
rsonal use only Chairman’s Address
Slide 8: Managing Director's Presentation on FY26 Results
rsonal use only Managing Director’s Presentation on FY26 Results 8
Slide 9: FY26 Financial Highlights
FY26 Financial Highlights Strong performance underpinned by adherence to long-term growth strategy rsonal use only $97.4m 35.5% Revenue ahead of guidance for $92-96m and up 13% on FY25 $86m. Gross margin improvement driven by innovation, product mix and increased benefits from vertical integration R
Slide 10: Operational Highlights – FY26
Operational Highlights – FY26 rsonal use only o Higher demand from infant o CholineXcel – patent has formula customers for Clover’s been registered and high-quality ARA powders. commercial packaging options are being o Melody Dairies delivering profit developed. margin benefits in line with expectat
Slide 11: Product Mix: Successful diversification from innovation
Product Mix: Successful diversification from innovation rsonal use only FY26 o Western manufacturers continue to increase market share o New product sales driven by customer and product diversification o Increased demand for ARA products FY25 o 1H market demand – western manufacturers increased mark
Slide 12: Financials
rsonal use only Financials 12
Slide 13: Profit and Loss FY26
Profit and Loss FY26 FY26 FY25 Profit & Loss Highlights Change rsonal use only $M $M o Revenue increased 13% driven by strong growth in ANZ and EU that more than offset declines in Asia and Americas. Revenue ($m) $97.4 $86.0 +13.3% o The gross profit margin increased to 35.5%, the positive result re
Slide 14: Balance Sheet July 2026
Balance Sheet 31 July 2026 FY26 FY25 Change Balance Sheet rsonal use only $M $M $M o Strong cash position maintained, reflecting the ongoing investment in inventory (+$19.8m in Cash 7.2 8.7 (1.5) FY26) that was partly offset by improved earnings performance and a more modest Trade Receivables 17.3 2
Slide 15: Operational Highlights
rsonal use only Operational Highlights 15
Slide 16: Ecuador facility: Sustainable Fish Oil Extraction
Ecuador facility: Sustainable Fish Oil Extraction rsonal use only Investment in crude fish oil supply chain is contributing to profit margins gains, with tuna oil steady at 30% of total raw material inputs in FY26. o Continuing to negotiate additional supply of high quality tuna heads. o Weather pat
Slide 17: New Zealand: processing and encapsulating of oils
New Zealand: processing and encapsulating of oils rsonal use only Melody Dairies facility Delivering high-quality Melody Dairies is Weekly use by Clover in Pursuing opportunities products with improved operating at near full manufacturing product to maximise outputs to plant use and efficiency capac
Slide 18: CholineXcel
CholineXcel TM o CholineXcel is a unique flowable powder that has broad based rsonal use only commercial applications, with near-term focus on the infant formula and nutraceutical market. o Samples have been presented to selected customers. o Intellectual Property process continues to advance, with
Slide 19: DHA & ARA Growth
DHA & ARA Growth rsonal use only DHA Growth (Omega 3) ARA Growth (Omega 6) • Product diversification into non- • Higher demand from infant formula allergenic, higher fortification levels customers for Clover’s high-quality and plant-based powders have ARA powders allowed Clover to deliver new soluti
Slide 20: USA Nutraceutical Market Development
USA USNutraceutical Market nutraceuticals market an emerging Development focus rsonal use only US is the world’s largest nutraceuticals market Clover to use nutraceuticals to spearhead US growth Continued diversification of nutraceuticals formats is positive for Clover’s encapsulation technologies a
Slide 21: Strategy and outlook
rsonal use only Strategy and outlook 21
Slide 22: Strategic focus
Strategic focus 1 Choline – market release, customer acceptance & initial orders & scaled manufacturing and certification rsonal use only 2 USA nutraceutical market development 3 Continued development of our distributor network 4 Investment in facilities & people 5 Continue focused innovation to fur
Slide 23: FY27 Outlook
FY27 Outlook rsonal use only Clover enters FY27 with positive momentum supported by continued demand for its nutritional products, the benefits of a vertically integrated high- quality supply chain and further expansion of its distribution network. These factors with product mix are contributing to
Slide 24: Disclaimer
Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such rsonal use only re
Slide 25: Formal Business
rsonal use only Formal Business 25
Slide 26: Adoption of annual accounts
rsonal use only 01 Adoption of annual accounts 26
Slide 27: Resolution 1: Adoption of remuneration report
rsonal use only 02 Resolution 1: Adoption of remuneration report 27
Slide 28: Remuneration Report proxy votes
rsonal use only For Voted 61,544,202 % 82.87 Resolution 1 Against 173,976 0.23 Open-Usable Abstain 12,546,733 232,160 16.90 N/A Remuneration Report Excluded 1,201,260 N/A 100.0 Proxy Votes 28
Slide 29: Resolution 2: Re-election of Mr. Ian Glasson
rsonal use only 03 Resolution 2: Re-election of Mr. Ian Glasson 29
Slide 30: Re-elect Mr. Ian Glasson proxy votes
rsonal use only Resolution 2 Voted % For 60,628,268 80.37 Against 2,251,729 2.99 Re-elect Mr. Ian Glasson Open-Usable 12,546,733 16.64 Abstain 211,601 N/A Proxy Votes Excluded 60,000 N/A 100.0 30
Slide 31: Resolution 3: Re-election of Ms. Toni Brendish
rsonal use only 04 Resolution 3: Re-election of Ms. Toni Brendish 31
Slide 32: Re-elect Ms. Toni Brendish proxy votes
rsonal use only Resolution 3 Voted % For 62,910,985 83.33 Against 26,460 0.04 Re-elect Ms. Toni Brendish Open-Usable 12,550,733 16.63 Abstain 210,153 N/A Proxy Votes Excluded - N/A 100.0 32
Slide 33: Resolution 4: Election of Mr. Brett Hewlett
rsonal use only 05 Resolution 4: Election of Mr. Brett Hewlett 33
Slide 34: Elect Mr. Brett Hewlett proxy votes
rsonal use only Voted % Resolution 4 For 60,700,973 80.40 Against 2,239,192 2.97 Open-Usable 12,546,033 16.63 Elect Mr. Brett Hewlett Abstain 212,133 N/A Excluded - N/A 100.0 Proxy Votes 34
Slide 35: Resolution 5: Approve acquisition of performance rights by the Managing Director
rsonal use only 06 Resolution 5: Approve acquisition of performance rights by the Managing Director 35
Slide 36: Performance Rights proxy votes
rsonal use only Resolution 5 Voted % For 59,970,209 80.10 Performance Rights Against Open-Usable 2,354,535 12,546,033 3.14 16.76 Managing Director Abstain 827,554 N/A Excluded - N/A 100.0 Proxy Votes 36
Slide 37: Voting poll & close
rsonal use only Voting poll & close 37
Slide 38: Questions
rsonal use only Questions 38